I

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Director – Applied AI Architect

AI Application EngineeringPosted on Nov 10
Full-timeRemote in USA$220k - $250k /yr

About the Job

Requirements

  • A Bachelor's degree in Computer Science, Engineering, or a related technical field, or equivalent experience.
  • At least 8 years of enterprise architecture, AI engineering, or a related technical discipline, including proficiency with AI coding agents and workflows.
  • Demonstrated experience building agentic AI solutions in a regulated environment.
  • Strong knowledge of cloud infrastructure and networking, enterprise data platforms, and system architecture.
  • Ability to collaborate effectively with business stakeholder teams.
  • Willingness and ability to travel approximately 25–40% of the time, including internationally.

Responsibilities

  • Define and maintain the company's AI architecture, establishing scalable standards and design patterns across business groups and functions.
  • Lead discovery with business teams to identify, qualify, and prioritize use cases tied to outcomes.
  • Apply understanding of modern AI systems, frontier large language models, agentic applications, model evaluation, retrieval, or enterprise AI workflows.
  • Partner with Research, Development, Medical, Commercial, and G&A functions to bridge business needs and technical execution, guide platform selection and integration, and make buy-versus-build decisions.
  • Establish practical guardrails and repeatable patterns that enable teams to move quickly and safely.
  • Provide technical leadership and mentorship to AI engineers and cross-functional stakeholders.
  • Monitor technology spend (FinOps) and optimize AI-related compute and token usage as adoption scales, adapting architectural approaches to an evolving AI cost landscape.

Desired Qualifications

  • A Master's degree.
  • Experience evaluating emerging AI technologies, frameworks, and platforms.

About the Company

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.

Company size
51-200
Company stage
IPO
Headquarters
New York City, New York
Founded
2016

Recently Posted Jobs

Explore more opportunities at Immunic Therapeutics

See more jobs